Radiation-induced upregulation of telomerase activity escapes PI3-kinase inhibition in two malignant glioma cell lines

Millet,P.; Granotier,C.; Etienne,O.; Boussin,F. D.

doi:10.3892/ijo.2013.1970

Radiation-induced upregulation of telomerase activity escapes PI3-kinase inhibition in two malignant glioma cell lines

Authors:
- P. Millet
- C. Granotier
- O. Etienne
- F. D. Boussin
View Affiliations

Affiliations: CEA, DSV-IRCM-SCSR, Laboratory of Radiopathology, UMR 967, F-92260 Fontenay‑aux‑Roses, France
Published online on: May 31, 2013 https://doi.org/10.3892/ijo.2013.1970
Pages: 375-382
Copyright: © Millet et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor relapse after radiotherapy is a great concern in the treatment of high-grade gliomas. Inhibition of the PI3-kinase/AKT pathway is known to radiosensitize cancer cells and to delay their DNA repair after irradiation. In this study, we show that the radiosensitization of CB193 and T98G, two high-grade glioma cell lines, by the PI3K inhibitor LY294002, correlates with the induction of G1 and G2/M arrest, but is inconsistently linked to a delayed DNA double-strand break (DSBs) repair. The PI3K/AKT pathway has been shown to activate radioprotective factors such as telomerase, whose inhibition may contribute to the radiosensitization of cancer cells. However, we show that radiation upregulates telomerase activity in LY-294002-treated glioma cells as well as untreated controls, demonstrating a PI3K/AKT-independent pathway of telomerase activation. Our study suggests that radiosensitizing strategies based on PI3-kinase inhibition in high-grade gliomas may be optimized by additional treatments targeting either telomerase activity or telomere maintenance.

View Figures

View References

1.	Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
2.	Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
3.	Stupp R, Hegi ME, Mason WP, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009.
4.	Koukourakis GV, Kouloulias V, Zacharias G, et al: Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article. Molecules. 14:1561–1577. 2009. View Article : Google Scholar : PubMed/NCBI
5.	Kondo Y, Hollingsworth EF and Kondo S: Molecular targeting for malignant gliomas (Review). Int J Oncol. 24:1101–1109. 2004.PubMed/NCBI
6.	Tanaka H, Yoshida M, Tanimura H, et al: The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res. 17:3272–3281. 2011. View Article : Google Scholar : PubMed/NCBI
7.	Jiang Z, Pore N, Cerniglia GJ, et al: Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. Cancer Res. 67:4467–4473. 2007. View Article : Google Scholar
8.	Mason WP, Belanger K, Nicholas G, et al: A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression. J Neurooncol. 107:343–349. 2011. View Article : Google Scholar : PubMed/NCBI
9.	Fassl A, Tagscherer KE, Richter J, et al: Notch1 signaling promotes survival of glioblastoma cells via EGFR-mediated induction of anti-apoptotic Mcl-1. Oncogene. 31:4698–4708. 2012. View Article : Google Scholar : PubMed/NCBI
10.	Stockhausen MT, Broholm H, Villingshoj M, et al: Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme. Exp Cell Res. 317:1513–1526. 2011. View Article : Google Scholar : PubMed/NCBI
11.	Ji XM, Xie CH, Fang MH, et al: Efficient inhibition of human telomerase activity by antisense oligonucleotides sensitizes cancer cells to radiotherapy. Acta Pharmacol Sin. 27:1185–1191. 2006. View Article : Google Scholar
12.	Chakravarti A, Zhai G, Suzuki Y, et al: The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol. 22:1926–1933. 2004. View Article : Google Scholar : PubMed/NCBI
13.	Kao GD, Jiang Z, Fernandes AM, Gupta AK and Maity A: Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation. J Biol Chem. 282:21206–21212. 2007. View Article : Google Scholar : PubMed/NCBI
14.	Gallia GL, Tyler BM, Hann CL, et al: Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells. Mol Cancer Ther. 8:386–393. 2009. View Article : Google Scholar : PubMed/NCBI
15.	Chautard E, Loubeau G, Tchirkov A, et al: Akt signaling pathway: a target for radiosensitizing human malignant glioma. Neurooncology. 12:434–443. 2010.PubMed/NCBI
16.	Carnero A, Blanco-Aparicio C, Renner O, Link W and Leal JF: The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets. 8:187–198. 2008. View Article : Google Scholar : PubMed/NCBI
17.	Sonoda Y, Ozawa T, Aldape KD, Deen DF, Berger MS and Pieper RO: Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res. 61:6674–6678. 2001.PubMed/NCBI
18.	Suzuki Y, Shirai K, Oka K, et al: Higher pAkt expression predicts a significant worse prognosis in glioblastomas. J Radiat Res. 51:343–348. 2010. View Article : Google Scholar : PubMed/NCBI
19.	Ermoian RP, Furniss CS, Lamborn KR, et al: Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin Cancer Res. 8:1100–1106. 2002.PubMed/NCBI
20.	Choe G, Horvath S, Cloughesy TF, et al: Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 63:2742–2746. 2003.
21.	Hayashi Y, Ueki K, Waha A, Wiestler OD, Louis DN and von Deimling A: Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol. 7:871–875. 1997. View Article : Google Scholar : PubMed/NCBI
22.	Sugawa N, Ekstrand AJ, James CD and Collins VP: Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA. 87:8602–8606. 1990. View Article : Google Scholar
23.	Huang HS, Nagane M, Klingbeil CK, et al: The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem. 272:2927–2935. 1997. View Article : Google Scholar
24.	Haas-Kogan D, Shalev N, Wong M, Mills G, Yount G and Stokoe D: Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol. 8:1195–1198. 1998. View Article : Google Scholar : PubMed/NCBI
25.	Li J, Yen C, Liaw D, et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science. 275:1943–1947. 1997. View Article : Google Scholar : PubMed/NCBI
26.	Myers MP, Pass I, Batty IH, et al: The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA. 95:13513–13518. 1998. View Article : Google Scholar : PubMed/NCBI
27.	Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE and Fuller GN: Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet. 25:55–57. 2000. View Article : Google Scholar : PubMed/NCBI
28.	Rajasekhar VK, Viale A, Socci ND, Wiedmann M, Hu X and Holland EC: Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell. 12:889–901. 2003. View Article : Google Scholar : PubMed/NCBI
29.	Smith JS, Tachibana I, Passe SM, et al: PTEN mutation, EGFR amplification and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 93:1246–1256. 2001. View Article : Google Scholar : PubMed/NCBI
30.	Knobbe CB, Merlo A and Reifenberger G: Pten signaling in gliomas. Neurooncology. 4:196–211. 2002.PubMed/NCBI
31.	Koul D: PTEN signaling pathways in glioblastoma. Cancer Biol Ther. 7:1321–1325. 2008. View Article : Google Scholar : PubMed/NCBI
32.	Li HF, Kim JS and Waldman T: Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. Radiat Oncol. 4:432009. View Article : Google Scholar : PubMed/NCBI
33.	Nakamura JL, Karlsson A, Arvold ND, et al: PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas. J Neurooncol. 71:215–222. 2005. View Article : Google Scholar : PubMed/NCBI
34.	Turriziani M, Di Giacomo AM, Cardillo A, et al: Residual telomerase activity: a marker of cell survival after exposure to gamma radiation in vitro. Anticancer Res. 23:4561–4569. 2003.PubMed/NCBI
35.	Wang X, Liu Y, Chow LS, et al: Regulation of telomerase activity by gamma-radiation in nasopharyngeal carcinoma cells. Anticancer Res. 20:433–437. 2000.PubMed/NCBI
36.	Perez Mdel R, Dubner D, Michelin S, Leteurtre F, Carosella ED and Gisone PA: Radiation-induced upregulation of telomerase in KG1a cells is influenced by dose-rate and radiation quality. Int J Radiat Biol. 78:1175–1183. 2002.PubMed/NCBI
37.	Wong KK, Chang S, Weiler SR, et al: Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation. Nat Genet. 26:85–88. 2000. View Article : Google Scholar : PubMed/NCBI
38.	Falchetti ML, Pallini R, D’Ambrosio E, et al: In situ detection of telomerase catalytic subunit mRNA in glioblastoma multiforme. Int J Cancer. 88:895–901. 2000. View Article : Google Scholar : PubMed/NCBI
39.	Huang F, Kanno H, Yamamoto I, Lin Y and Kubota Y: Correlation of clinical features and telomerase activity in human gliomas. J Neurooncol. 43:137–142. 1999. View Article : Google Scholar : PubMed/NCBI
40.	Harada K, Kurisu K, Tahara H, Tahara E and Ide T: Telomerase activity in primary and secondary glioblastomas multiforme as a novel molecular tumor marker. J Neurosurg. 93:618–625. 2000. View Article : Google Scholar : PubMed/NCBI
41.	Fukushima T, Yoshino A, Katayama Y, Watanabe T, Kusama K and Moro I: Prediction of clinical course of diffusely infiltrating astrocytomas from telomerase expression and quantitated activity level. Cancer Lett. 187:191–198. 2002. View Article : Google Scholar : PubMed/NCBI
42.	Boldrini L, Pistolesi S, Gisfredi S, et al: Telomerase activity and hTERT mRNA expression in glial tumors. Int J Oncol. 28:1555–1560. 2006.PubMed/NCBI
43.	Wesbuer S, Lanvers-Kaminsky C, Duran-Seuberth I, et al: Association of telomerase activity with radio- and chemosensitivity of neuroblastomas. Radiat Oncol. 5:662010. View Article : Google Scholar : PubMed/NCBI
44.	Merle P, Evrard B, Petitjean A, et al: Telomere targeting with a new G4 ligand enhances radiation-induced killing of human glioblastoma cells. Mol Cancer Ther. 10:1784–1795. 2011. View Article : Google Scholar : PubMed/NCBI
45.	Marian CO, Cho SK, McEllin BM, et al: The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res. 16:154–163. 2010. View Article : Google Scholar
46.	Zhou FX, Liao ZK, Dai J, et al: Radiosensitization effect of zidovudine on human malignant glioma cells. Biochem Biophys Res Commun. 354:351–356. 2007. View Article : Google Scholar : PubMed/NCBI
47.	Kang SS, Kwon T, Kwon DY and Do SI: Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem. 274:13085–13090. 1999. View Article : Google Scholar
48.	Zhou C, Bae-Jump VL, Whang YE, Gehrig PA and Boggess JF: The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels. Gynecol Oncol. 101:305–310. 2006. View Article : Google Scholar : PubMed/NCBI
49.	Uziel O, Fenig E, Nordenberg J, et al: Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer. 92:1881–1891. 2005. View Article : Google Scholar : PubMed/NCBI
50.	Leteurtre F, Li X, Gluckman E and Carosella ED: Telomerase activity during the cell cycle and in gamma-irradiated hematopoietic cells. Leukemia. 11:1681–1689. 1997. View Article : Google Scholar : PubMed/NCBI
51.	Finnon P, Silver AR and Bouffler SD: Upregulation of telomerase activity by X-irradiation in mouse leukaemia cells is independent of Tert, Terc, Tnks and Myc transcription. Carcinogenesis. 21:573–578. 2000. View Article : Google Scholar : PubMed/NCBI
52.	Hande MP, Balajee AS and Natarajan AT: Induction of telomerase activity by UV-irradiation in Chinese hamster cells. Oncogene. 15:1747–1752. 1997. View Article : Google Scholar : PubMed/NCBI
53.	Hyeon Joo O, Hande MP, Lansdorp PM and Natarajan AT: Induction of telomerase activity and chromosome aberrations in human tumour cell lines following X-irradiation. Mutat Res. 401:121–131. 1998.PubMed/NCBI
54.	Ram R, Uziel O, Eldan O, et al: Ionizing radiation upregulates telomerase activity in cancer cell lines by post-translational mechanism via ras/phosphatidylinositol 3-kinase/Akt pathway. Clin Cancer Res. 15:914–923. 2009. View Article : Google Scholar
55.	Lefranc F, Rynkowski M, DeWitte O and Kiss R: Present and potential future adjuvant issues in high-grade astrocytic glioma treatment. Adv Tech Stand Neurosurg. 34:3–35. 2009.PubMed/NCBI
56.	Cully M, You H, Levine AJ and Mak TW: Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 6:184–192. 2006. View Article : Google Scholar : PubMed/NCBI
57.	Hennessy BT, Smith DL, Ram PT, Lu Y and Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 4:988–1004. 2005. View Article : Google Scholar : PubMed/NCBI
58.	Vlahos CJ, Matter WF, Hui KY and Brown RF: A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem. 269:5241–5248. 1994.PubMed/NCBI
59.	Menet A, Speth C, Larcher C, et al: Epstein-Barr virus infection of human astrocyte cell lines. J Virol. 73:7722–7733. 1999.PubMed/NCBI
60.	Pennarun G, Granotier C, Gauthier LR, et al: Apoptosis related to telomere instability and cell cycle alterations in human glioma cells treated by new highly selective G-quadruplex ligands. Oncogene. 24:2917–2928. 2005. View Article : Google Scholar
61.	Walker SM, Leslie NR, Perera NM, Batty IH and Downes CP: The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif. Biochem J. 379:301–307. 2004. View Article : Google Scholar : PubMed/NCBI
62.	Sano T, Asai A, Mishima K, Fujimaki T and Kirino T: Telomerase activity in 144 brain tumours. Br J Cancer. 77:1633–1637. 1998. View Article : Google Scholar : PubMed/NCBI
63.	Liang J and Slingerland JM: Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle. 2:339–345. 2003. View Article : Google Scholar : PubMed/NCBI
64.	Olive PL: Detection of DNA damage in individual cells by analysis of histone H2AX phosphorylation. Methods Cell Biol. 75:355–373. 2004. View Article : Google Scholar : PubMed/NCBI
65.	Nowak E, Etienne O, Millet P, et al: Radiation-induced H2AX phosphorylation and neural precursor apoptosis in the developing brain of mice. Radiat Res. 165:155–164. 2006. View Article : Google Scholar : PubMed/NCBI
66.	Rogakou EP, Pilch DR, Orr AH, Ivanova VS and Bonner WM: DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 273:5858–5868. 1998. View Article : Google Scholar : PubMed/NCBI
67.	Fernandez-Capetillo O, Lee A, Nussenzweig M and Nussenzweig A: H2AX: the histone guardian of the genome. DNA Repair. 3:959–967. 2004. View Article : Google Scholar : PubMed/NCBI
68.	Stiff T, O’Driscoll M, Rief N, Iwabuchi K, Lobrich M and Jeggo PA: ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res. 64:2390–2396. 2004. View Article : Google Scholar : PubMed/NCBI
69.	Hiraga S, Ohnishi T, Izumoto S, et al: Telomerase activity and alterations in telomere length in human brain tumors. Cancer Res. 58:2117–2125. 1998.PubMed/NCBI
70.	Tchirkov A, Rolhion C, Kemeny JL, et al: Clinical implications of quantitative real-time RT-PCR analysis of hTERT gene expression in human gliomas. Br J Cancer. 88:516–520. 2003. View Article : Google Scholar : PubMed/NCBI
71.	Shervington A, Patel R, Lu C, et al: Telomerase subunits expression variation between biopsy samples and cell lines derived from malignant glioma. Brain Res. 1134:45–52. 2007. View Article : Google Scholar : PubMed/NCBI
72.	Hirao T, Urata Y, Kageyama K, et al: Dehydroepiandrosterone augments sensitivity to gamma-ray irradiation in human H4 neuroglioma cells through down-regulation of Akt signaling. Free Radic Res. 42:957–965. 2008. View Article : Google Scholar
73.	Ramaswamy S, Nakamura N, Vazquez F, et al: Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA. 96:2110–2115. 1999. View Article : Google Scholar : PubMed/NCBI
74.	Gottschalk AR, Basila D, Wong M, et al: p27^Kip1is required for PTEN-induced G1 growth arrest. Cancer Res. 61:2105–2111. 2001.PubMed/NCBI
75.	Liang J, Zubovitz J, Petrocelli T, et al: PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med. 8:1153–1160. 2002. View Article : Google Scholar : PubMed/NCBI
76.	Rosenzweig KE, Youmell MB, Palayoor ST and Price BD: Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. Clin Cancer Res. 3:1149–1156. 1997.
77.	Park JK, Jung HY, Park SH, et al: Combination of PTEN and gamma-ionizing radiation enhances cell death and G(2)/M arrest through regulation of AKT activity and p21 induction in non-small-cell lung cancer cells. Int J Radiat Oncol Biol Phys. 70:1552–1560. 2008. View Article : Google Scholar : PubMed/NCBI
78.	Toulany M, Kehlbach R, Florczak U, et al: Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair. Mol Cancer Ther. 7:1772–1781. 2008. View Article : Google Scholar : PubMed/NCBI
79.	Shtivelman E, Sussman J and Stokoe D: A role for PI 3-kinase and PKB activity in the G2/M phase of the cell cycle. Curr Biol. 12:919–924. 2002. View Article : Google Scholar : PubMed/NCBI
80.	Lee SR, Park JH, Park EK, Chung CH, Kang SS and Bang OS: Akt-induced promotion of cell-cycle progression at G2/M phase involves upregulation of NF-Y binding activity in PC12 cells. J Cell Physiol. 205:270–277. 2005. View Article : Google Scholar : PubMed/NCBI
81.	He L, Yang X, Cao X, Liu F, Quan M and Cao J: Casticin induces growth suppression and cell cycle arrest through activation of FOXO3a in hepatocellular carcinoma. Oncol Rep. 29:103–108. 2013.PubMed/NCBI
82.	Chung J, Khadka P and Chung IK: Nuclear import of hTERT requires a bipartite nuclear localization signal and Akt-mediated phosphorylation. J Cell Sci. 125:2684–2697. 2012. View Article : Google Scholar
83.	Neuhof D, Zwicker F, Kuepper JH, Debus J and Weber KJ: Activation of telomerase by ionizing radiation: differential response to the inhibition of DNA double-strand break repair by abrogation of poly (ADP-ribosyl)ation, by LY294002, or by Wortmannin. Int J Radiat Oncol Biol Phys. 69:887–894. 2007. View Article : Google Scholar : PubMed/NCBI
84.	Fu W, Begley JG, Killen MW and Mattson MP: Anti-apoptotic role of telomerase in pheochromocytoma cells. J Biol Chem. 274:7264–7271. 1999. View Article : Google Scholar : PubMed/NCBI
85.	Blackburn EH: Switching and signaling at the telomere. Cell. 106:661–673. 2001. View Article : Google Scholar : PubMed/NCBI
86.	Akiyama M, Yamada O, Kanda N, et al: Telomerase overexpression in K562 leukemia cells protects against apoptosis by serum deprivation and double-stranded DNA break inducing agents, but not against DNA synthesis inhibitors. Cancer Lett. 178:187–197. 2002. View Article : Google Scholar
87.	Masutomi K, Possemato R, Wong JM, et al: The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc Natl Acad Sci USA. 102:8222–8227. 2005. View Article : Google Scholar
88.	Ferrandon S, Saultier P, Carras J, et al: Telomere profiling: toward glioblastoma personalized medicine. Mol Neurobiol. 47:64–76. 2013. View Article : Google Scholar : PubMed/NCBI